CA2154787A1 - Selective cell proliferation - Google Patents
Selective cell proliferationInfo
- Publication number
- CA2154787A1 CA2154787A1 CA002154787A CA2154787A CA2154787A1 CA 2154787 A1 CA2154787 A1 CA 2154787A1 CA 002154787 A CA002154787 A CA 002154787A CA 2154787 A CA2154787 A CA 2154787A CA 2154787 A1 CA2154787 A1 CA 2154787A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell population
- cell
- bsfm
- hematopoietic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004663 cell proliferation Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 821
- 238000000034 method Methods 0.000 claims abstract description 240
- 210000000130 stem cell Anatomy 0.000 claims abstract description 118
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 44
- 239000011886 peripheral blood Substances 0.000 claims abstract description 44
- 239000002243 precursor Substances 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 238000002054 transplantation Methods 0.000 claims abstract description 15
- 210000000056 organ Anatomy 0.000 claims abstract description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 65
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 51
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 48
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 47
- 239000002609 medium Substances 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 230000035755 proliferation Effects 0.000 claims description 22
- 210000003743 erythrocyte Anatomy 0.000 claims description 21
- 230000003394 haemopoietic effect Effects 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 238000012258 culturing Methods 0.000 claims description 20
- 210000000777 hematopoietic system Anatomy 0.000 claims description 20
- 239000003226 mitogen Substances 0.000 claims description 19
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 18
- 210000002540 macrophage Anatomy 0.000 claims description 18
- 238000001727 in vivo Methods 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 230000001939 inductive effect Effects 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000000926 separation method Methods 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 210000001616 monocyte Anatomy 0.000 claims description 13
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 210000003714 granulocyte Anatomy 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical group O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 claims description 11
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 claims description 11
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 10
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 10
- 210000001772 blood platelet Anatomy 0.000 claims description 10
- 210000002798 bone marrow cell Anatomy 0.000 claims description 10
- -1 diterpene ester Chemical class 0.000 claims description 10
- 230000001605 fetal effect Effects 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 210000004698 lymphocyte Anatomy 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 230000035899 viability Effects 0.000 claims description 9
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 210000004700 fetal blood Anatomy 0.000 claims description 8
- 230000017423 tissue regeneration Effects 0.000 claims description 8
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 108010054147 Hemoglobins Proteins 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 210000003979 eosinophil Anatomy 0.000 claims description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 5
- 229920001917 Ficoll Polymers 0.000 claims description 5
- 108010002386 Interleukin-3 Proteins 0.000 claims description 5
- 108010089814 Plant Lectins Proteins 0.000 claims description 5
- 240000003864 Ulex europaeus Species 0.000 claims description 5
- 210000003651 basophil Anatomy 0.000 claims description 5
- 210000003013 erythroid precursor cell Anatomy 0.000 claims description 5
- 239000003726 plant lectin Substances 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 229930004069 diterpene Natural products 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 230000009395 genetic defect Effects 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 210000000066 myeloid cell Anatomy 0.000 claims description 4
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 claims description 4
- QGVLYPPODPLXMB-UBTYZVCOSA-N phorbol group Chemical group O[C@@]12CC(=C[C@@H]3[C@@]([C@@H]2C=C(C1=O)C)([C@@H]([C@H]([C@@]1([C@H]3C1(C)C)O)O)C)O)CO QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 108010062580 Concanavalin A Proteins 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 108010002616 Interleukin-5 Proteins 0.000 claims description 3
- 108090001007 Interleukin-8 Proteins 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 235000010730 Ulex europaeus Nutrition 0.000 claims description 3
- 210000002449 bone cell Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 230000008774 maternal effect Effects 0.000 claims description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- HJEHMBCPVHLCOG-UHFFFAOYSA-N 1-ethynyl-4-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=C(C#C)C=C1 HJEHMBCPVHLCOG-UHFFFAOYSA-N 0.000 claims description 2
- NQSPTMFCJGKOQJ-UHFFFAOYSA-N 2,2,2-trifluoro-1-(3-fluorophenyl)ethanone Chemical compound FC1=CC=CC(C(=O)C(F)(F)F)=C1 NQSPTMFCJGKOQJ-UHFFFAOYSA-N 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 241000218211 Maclura Species 0.000 claims description 2
- 241000219822 Macrotyloma axillare Species 0.000 claims description 2
- 235000001504 Macrotyloma uniflorum var. uniflorum Nutrition 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 240000007643 Phytolacca americana Species 0.000 claims description 2
- 235000009074 Phytolacca americana Nutrition 0.000 claims description 2
- 240000004713 Pisum sativum Species 0.000 claims description 2
- 235000010582 Pisum sativum Nutrition 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 240000003768 Solanum lycopersicum Species 0.000 claims description 2
- 244000046101 Sophora japonica Species 0.000 claims description 2
- 235000010586 Sophora japonica Nutrition 0.000 claims description 2
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 2
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000003321 cartilage cell Anatomy 0.000 claims description 2
- 210000002791 cfu-m Anatomy 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 231100000655 enterotoxin Toxicity 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- BQJRUJTZSGYBEZ-YVQNUNKESA-N phorbol 12,13-dibutanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-YVQNUNKESA-N 0.000 claims description 2
- DGOSGFYDFDYMCW-MWRBZVGOSA-N phorbol dicaprate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCCCCCCCC)C1(C)C DGOSGFYDFDYMCW-MWRBZVGOSA-N 0.000 claims description 2
- XLCISDOVNFLSGO-VONOSFMSSA-N phorbol-12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(O)C1(C)C XLCISDOVNFLSGO-VONOSFMSSA-N 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 210000004989 spleen cell Anatomy 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 7
- 230000002708 enhancing effect Effects 0.000 claims 4
- 206010061598 Immunodeficiency Diseases 0.000 claims 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 3
- 230000007813 immunodeficiency Effects 0.000 claims 3
- 230000001010 compromised effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000010257 thawing Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 244000045232 Canavalia ensiformis Species 0.000 claims 1
- 235000010520 Canavalia ensiformis Nutrition 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 108010015133 Galactose oxidase Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 244000061456 Solanum tuberosum Species 0.000 claims 1
- 235000002595 Solanum tuberosum Nutrition 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000002960 bfu-e Anatomy 0.000 claims 1
- 210000000751 eop Anatomy 0.000 claims 1
- 238000012252 genetic analysis Methods 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 108010075210 streptolysin O Proteins 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 abstract description 26
- 238000002560 therapeutic procedure Methods 0.000 abstract description 23
- 230000004069 differentiation Effects 0.000 abstract description 11
- 210000004789 organ system Anatomy 0.000 abstract description 6
- 238000001415 gene therapy Methods 0.000 abstract description 4
- 230000009469 supplementation Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 description 20
- 239000000047 product Substances 0.000 description 17
- 238000004113 cell culture Methods 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 230000002068 genetic effect Effects 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 230000001332 colony forming effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 208000009329 Graft vs Host Disease Diseases 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 208000024908 graft versus host disease Diseases 0.000 description 9
- 210000004976 peripheral blood cell Anatomy 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 102000055151 human KITLG Human genes 0.000 description 7
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 239000007640 basal medium Substances 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000011132 hemopoiesis Effects 0.000 description 6
- 210000004153 islets of langerhan Anatomy 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000001000 micrograph Methods 0.000 description 5
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000013925 CD34 antigen Human genes 0.000 description 4
- 108050003733 CD34 antigen Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 4
- 102100039064 Interleukin-3 Human genes 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000000925 erythroid effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 102000046949 human MSC Human genes 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 210000003593 megakaryocyte Anatomy 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- 241000237074 Centris Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000044890 human EPO Human genes 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- HAAITRDZHUANGT-UHFFFAOYSA-N 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 HAAITRDZHUANGT-UHFFFAOYSA-N 0.000 description 1
- 208000012124 AIDS-related disease Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 206010002965 Aplasia pure red cell Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 201000008162 B cell deficiency Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000220451 Canavalia Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 206010010162 Complications of bone marrow transplant Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000228957 Ferula foetida Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000001905 GM2 Gangliosidoses Diseases 0.000 description 1
- 201000008905 GM2 gangliosidosis Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001126084 Homo sapiens Piwi-like protein 2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102100029365 Piwi-like protein 2 Human genes 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 235000003846 Ricinus Nutrition 0.000 description 1
- 241000322381 Ricinus <louse> Species 0.000 description 1
- 101150089644 Rnls gene Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000010346 Sphingolipidoses Diseases 0.000 description 1
- 201000001307 Sphingolipidosis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 101100242191 Tetraodon nigroviridis rho gene Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 101001089018 Ulex europaeus Anti-H(O) lectin 1 Proteins 0.000 description 1
- 101001023076 Ulex europaeus Anti-H(O) lectin 2 Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000009614 adult lymphoma Diseases 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 201000006387 myelophthisic anemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/59—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US959393A | 1993-01-27 | 1993-01-27 | |
| US18837694A | 1994-01-25 | 1994-01-25 | |
| US08/188,376 | 1994-01-25 | ||
| US08/009,593 | 1994-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2154787A1 true CA2154787A1 (en) | 1994-08-04 |
Family
ID=26679661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002154787A Abandoned CA2154787A1 (en) | 1993-01-27 | 1994-01-26 | Selective cell proliferation |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0752867A4 (de) |
| JP (1) | JPH08511935A (de) |
| AU (1) | AU6167394A (de) |
| CA (1) | CA2154787A1 (de) |
| WO (1) | WO1994016715A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06508528A (ja) * | 1992-03-23 | 1994-09-29 | ネクセル セラピューティクス インコーポレーテッド | インビトロ由来ヒト好中球前駆体細胞 |
| US5580724A (en) * | 1994-03-25 | 1996-12-03 | Board Of Regents, The University Of Texas System | Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis |
| US5827742A (en) * | 1994-09-01 | 1998-10-27 | Beth Israel Deaconess Medical Center, Inc. | Method of selecting pluripotent hematopioetic progenitor cells |
| US5505908A (en) * | 1994-09-01 | 1996-04-09 | Halozone Technologies, Inc. | Recycling and recovery of methyl bromide fumigant |
| JP3217278B2 (ja) * | 1996-10-21 | 2001-10-09 | 株式会社 エフェクト | 落花生種皮処理物を用いた造血機能回復剤及び加工食品 |
| US6258361B1 (en) | 1996-10-21 | 2001-07-10 | Akio Yoshihara | Agent for recovering hematopoietic function and processed food both containing treated product of peanut seed coats |
| US6194207B1 (en) * | 1997-01-31 | 2001-02-27 | Hemosol Inc. | Methods for the selective expansion of lymphocytes by in vitro cultivation |
| AU6346898A (en) * | 1997-03-06 | 1998-09-22 | University Of Massachusetts | Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters |
| CA2326378A1 (en) * | 1998-04-24 | 1999-11-04 | Hemosol Inc. | Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects |
| JP2002523039A (ja) * | 1998-08-24 | 2002-07-30 | ティー．ブリーダーズ，インコーポレイテッド | 非胎児血管芽細胞を含む細胞集団、およびその生産方法 |
| GB2343679A (en) * | 1998-11-16 | 2000-05-17 | Alison Miriam Davies | Autologous transplantation and method for making cells dormant |
| JP2003513624A (ja) * | 1999-10-29 | 2003-04-15 | マクギル・ユニヴァーシティ | 脱分化した細胞を調製するための培地 |
| GB2379446A (en) * | 2000-05-16 | 2003-03-12 | Alison Davies | Cells,culture methods and their uses |
| WO2008048931A1 (en) * | 2006-10-16 | 2008-04-24 | Celula Inc. | Methods and compositions for differential expansion of fetal cells in maternal blood and their use |
| EP2028267A1 (de) * | 2007-08-21 | 2009-02-25 | Charite-Universitätsmedizin Berlin | Verwendung zur Herstellung von homologen zellulären Blutkomponenten aus hematopoietischen Vorläuferzellen |
| JP2022501592A (ja) * | 2018-09-20 | 2022-01-06 | ウースター・ポリテクニック・インスティテュートWorcester Polytechnic Institute | 優先的接着に基づいて細胞を捕捉する方法 |
| IN201921052318A (de) * | 2019-12-17 | 2019-12-20 | Senthilkumar NATESAN | |
| US20240060044A1 (en) * | 2021-02-25 | 2024-02-22 | Senthilkumar NATESAN | A novel method of generating t cells from peripheral blood precursors and their uses thereof |
| CN115927169B (zh) * | 2022-10-11 | 2023-08-11 | 再造再生医学科技(杭州)有限公司 | 用于扩增cd34+造血干细胞的培养液和体外扩增cd34+造血干细胞的方法 |
-
1994
- 1994-01-26 WO PCT/US1994/001033 patent/WO1994016715A1/en not_active Application Discontinuation
- 1994-01-26 JP JP6517354A patent/JPH08511935A/ja active Pending
- 1994-01-26 CA CA002154787A patent/CA2154787A1/en not_active Abandoned
- 1994-01-26 AU AU61673/94A patent/AU6167394A/en not_active Abandoned
- 1994-01-26 EP EP94908664A patent/EP0752867A4/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0752867A1 (de) | 1997-01-15 |
| AU6167394A (en) | 1994-08-15 |
| WO1994016715A1 (en) | 1994-08-04 |
| EP0752867A4 (de) | 1997-07-23 |
| JPH08511935A (ja) | 1996-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5472867A (en) | Ex vivo expansion of peripheral blood progenitor cells | |
| CA2154787A1 (en) | Selective cell proliferation | |
| US7625752B2 (en) | Cellular compositions and methods of making and using them | |
| Sandstrom et al. | Effects of CD34+ cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells | |
| US7790458B2 (en) | Material and methods for the growth of hematopoietic stem cells | |
| EP0812201B1 (de) | In vitro vermehrung von stammzellen | |
| US7863043B2 (en) | Stem cell populations and methods of use | |
| US20050221482A1 (en) | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof | |
| WO2007146432A2 (en) | Processing procedure for peripheral blood stem cells | |
| CN101848991A (zh) | 分离的细胞群 | |
| KR20080072748A (ko) | 줄기세포 귀소 및 생착을 향상시키는 방법 | |
| JPH06508528A (ja) | インビトロ由来ヒト好中球前駆体細胞 | |
| JPH08509377A (ja) | ヒトのエリスロイド前駆細胞集団 | |
| US20020160512A1 (en) | Ex vivo expansion of mammalian hematopoietic stem cells | |
| US20060280727A1 (en) | Dendritic cell isolation methods | |
| KR20050042046A (ko) | 조혈 줄기세포의 증식방법 | |
| Gluckman | Ex vivo expansion of cord blood cells | |
| CN113073078B (zh) | 脐带来源间充质干细胞制备的通用型血小板制剂及方法 | |
| US20060084170A1 (en) | Cytokine-free growth and maintenance of progenitor cells | |
| Mahmud et al. | Growth factors mobilize CXCR4 low/negative primitive hematopoietic stem/progenitor cells from the bone marrow of nonhuman primates | |
| EP1881063A1 (de) | Stammzellpopulationen und deren Verwendung | |
| JP2022017977A (ja) | 細胞、組成物及び治療用組成物 | |
| Engelhardt et al. | Progenitor cell expansion-Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy | |
| WO1999000486A1 (en) | Compositions and methods for inducing the development and differentiation of hemopoietic stem cells | |
| NZ530904A (en) | Use of oligopeptides corresponding to the C-terminal portion of OGP that enhance treatments such as engraftment of bone marrow transplants and haematopoietic reconstruction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |